Clonal hematopoiesis in patients with stem cell mobilization failure: a nested case-control study

Key Points • CH is common at the time of stem cell mobilization in poor mobilizers and matched controls.• Mutations in PPM1D and TP53 correspond with poor stem cell mobilization.

[1]  Andrew T Nguyen,et al.  Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms , 2022, Blood.

[2]  J. Vonk,et al.  Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged ≥80 years. , 2021, Blood advances.

[3]  L. Hesson,et al.  Poor mobilization of autologous CD34+ peripheral blood stem cells in haematology patients undergoing autologous stem cell transplantation is associated with the presence of variants in genes implicated in clonal haematopoiesis of indeterminant potential , 2021, British journal of haematology.

[4]  M. Konopleva,et al.  Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. , 2020, Blood advances.

[5]  Stuart M. Gardos,et al.  Cancer therapy shapes the fitness landscape of clonal hematopoiesis , 2020, Nature Genetics.

[6]  C. Peano,et al.  Clinical Relevance of Clonal Hematopoiesis in the Oldest-Old Population , 2020, SSRN Electronic Journal.

[7]  A. Viale,et al.  Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes , 2020, Nature Medicine.

[8]  G. Getz,et al.  Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant , 2020, Nature Communications.

[9]  M. M. van der Klauw,et al.  Mutational spectrum and dynamics of clonal hematopoiesis in anemia of older individuals. , 2020, Blood.

[10]  J. W. Hansen,et al.  Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study , 2020, Leukemia.

[11]  P. Hokland,et al.  Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms post-autologous stem cell transplantation. , 2020, Blood advances.

[12]  D. de Jong,et al.  Dynamic clonal hematopoiesis and functional T-cell immunity in a supercentenarian , 2019, Leukemia.

[13]  H. Kantarjian,et al.  Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia , 2019, Cancer.

[14]  S. Ogawa,et al.  Predisposed genomic instability in pre-treatment bone marrow evolves to therapy-related myeloid neoplasms in malignant lymphoma , 2019, Haematologica.

[15]  Annette S. Kim,et al.  Clonal haematopoiesis of indeterminate potential among cancer survivors exposed to myelotoxic chemotherapy , 2019, British journal of haematology.

[16]  L. Bullinger,et al.  Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  P. A. Futreal,et al.  PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy , 2018, Cell stem cell.

[18]  S. Carr,et al.  PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells. , 2018, Blood.

[19]  S. Miyano,et al.  Early detection and evolution of preleukemic clones in therapy-related myeloid neoplasms following autologous SCT. , 2018, Blood.

[20]  Markus G. Manz,et al.  Molecular Minimal Residual Disease in Acute Myeloid Leukemia , 2018, The New England journal of medicine.

[21]  Christopher A. Miller,et al.  Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential , 2018, Nature Communications.

[22]  M. Ladanyi,et al.  Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. , 2017, Cell stem cell.

[23]  Kari Stefansson,et al.  Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. , 2017, Blood.

[24]  D. Neuberg,et al.  Prognostic Mutations in Myelodysplastic Syndrome after Stem‐Cell Transplantation , 2017, The New England journal of medicine.

[25]  A. LaCasce,et al.  Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  H. McLeod,et al.  Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. , 2017, The Lancet. Oncology.

[27]  B. Ebert,et al.  Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. , 2015, Blood.

[28]  D. Neuberg,et al.  Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. , 2015, Blood.

[29]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.

[30]  S. Gabriel,et al.  Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. , 2014, The New England journal of medicine.

[31]  E. Thiel,et al.  Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas , 2013, Haematologica.

[32]  C Tarella,et al.  Proposed definition of ‘poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo , 2011, Bone Marrow Transplantation.

[33]  H. Goldschmidt,et al.  Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[34]  F. Ravagnani,et al.  Management of poor peripheral blood stem cell mobilization: incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions. , 2009, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[35]  A. Nademanee,et al.  Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. , 2009, Blood.

[36]  U. Popat,et al.  Poor hematopoietic stem cell mobilizers: A single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma , 2009, American journal of hematology.

[37]  B. Barlogie,et al.  Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989. , 2008, Blood.

[38]  B. Barlogie,et al.  Mobilization of CD34+ cells in elderly patients (≥ 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen , 2003, British journal of haematology.

[39]  Masaaki Adachi,et al.  p53‐inducible Wip1 phosphatase mediates a negative feedback regulation of p38 MAPK‐p53 signaling in response to UV radiation , 2000, The EMBO journal.

[40]  M. Fiscella,et al.  Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[41]  R. Storb,et al.  Factors that influence collection and engraftment of autologous peripheral-blood stem cells. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.